

## **Supplementary Data**

### **Table of content**

- 1. Supplementary description of RNA extraction and RT-PCR methods**
  - 1a. RNA extraction RT-PCR for SARS-CoV-2 and quantification**
  - 1b. RT-PCR for subgenomic RNA for SARS-CoV-2**
  - 1c. RT-PCR for other respiratory viruses**
  
- 2. Supplementary description of cell culture and antibody detection methods**
  - 2a. Virus isolation**
  - 2b. Recombinant SARS-CoV-2 spike protein-based immunofluorescence test**
  - 2c. Plaque reduction neutralization test (PRNT) for SARS-CoV 2**
  
- 3. Supplementary table S1**
  
- 4. Supplementary figures**
  - 3a. Figure S1. Sequence analysis of E gene sgRNA**
  - 3b. Figure S2. Representative outcome of a recombinant immunofluorescence test**
  
- 5. Supplementary references**

## **1. Supplementary description of RNA extraction and RT-PCR methods**

### **a. RNA extraction RT-PCR for SARS-CoV-2 and quantification**

RNA was extracted from clinical samples by using the viral RNA mini kit (Qiagen, Hilden Germany) following the manufacturer's instructions. Sputum samples were diluted 1:3 and stool samples 1:5 in phosphate-buffered saline, mixed, and briefly centrifuged before RNA extraction. Real-time RT-PCR for SARS-CoV-2 was performed on RNA extracts with RT-PCR targets in the E- and RdRp genes, as described<sup>1</sup>. Both laboratories used a pre-formulated oligonucleotide mixture (Tib-Molbiol, Berlin, Germany) to make laboratory procedures more reproducible. In cases of PCR inhibition, samples were re-tested in 1:10 and 1:100 dilutions.

### **b. RT-PCR for subgenomic RNA for SARS-CoV-2**

Testing for sgRNA used a leader-specific primer, as well as primers and probes targeting sequences downstream of the start codons of the E gene, as described<sup>1</sup>. In addition to real-time RT-PCR readouts, RT-PCR products for sgRNAs were analyzed on agarose gel and Sanger sequenced (**Figure S1**). The oligonucleotide sequence of the leader specific primer was as follows: sgLeadSARSCoV2-F; CGATCTCTTGATAGATCTGTTCTC. The sgRNA RT-PCR assay used the Superscript III one-step RT-PCR system with Platinum Taq Polymerase (Invitrogen, Darmstadt, Germany) with 400 nM concentrations of each of the primers, as well as 200 nM of probe. Thermal cycling involved 10 min at 50 °C for reverse transcription, followed by 3 min at 95 °C and 45 cycles of 10 s at 95 °C, 15 s at 56 °C, and 5 s at 72 °C.

### **c. RT-PCR for other respiratory viruses**

All patients (one sputum and one oro- or nasopharyngeal throat swab from each) were tested for other respiratory viruses using LightMix-Modular Assays (Roche, Penzberg, Germany). These PCR assays test for presence of HCoV-HKU1, -OC43, -NL63, -229E; Influenza virus A and B, Rhinovirus, Enterovirus, Respiratory syncytial virus, Human Parainfluenza virus 1-4, Human metapneumovirus, Adenovirus, and Human bocavirus RNA or DNA.

## **2. Supplementary description of cell culture and antibody detection methods**

### **a. Virus isolation**

Vero E6 (ATCC CRL-1586) cells were seeded on a 24-well plate at  $3.5 \times 10^5$  cells/mL in Dulbecco modified Eagle medium (DMEM) containing 1% sodium pyruvate, 1% nonessential amino acids, 1% l-glutamine, and 10% fetal calf serum (FCS; all Gibco, Darmstadt, Germany) one day prior to infection.

Sputum and swabs from patients were diluted in 2 ml OptiPro serum-free medium (Gibco) to reduce viscosity and improve pipetting. Stool samples were dissolved in 3 mL OptiPro medium. Stool samples were centrifuged for 30 min at 300 x g and 4°C. The supernatant of the stool samples was further diluted (1:5 and 1:50) in OptiPro medium and passed through a 0.45 µm-sized filter.

Vero E6 cells were inoculated with 100 µl processed patient sample (100 µl) at 37°C for 1 hour. Then, cells were washed ones with phosphate-buffered saline (Gibco) and supplied with 500 µl DMEM composite as described above, except for a reduced FCS content of 2% and 1% amphotericin B. Cells were controlled daily for cytopathogenic effects for 6 days. Every 2 days or upon observation of cytopathogenic effects, 50 µl of cell culture supernatant was subjected to viral RNA extraction and SARS-CoV-2 specific real-time RT-PCR using the SARS-2-CoV E assay. Supernatants of positively tested wells were harvested, centrifuged at 200 × g for 3 min to remove cell debris and diluted 1:2 in OptiPro containing 0.5% gelatin for storage.

#### **b. Recombinant SARS-CoV-2 spike protein-based immunofluorescence test**

VeroB4 cells were transfected with pCG1-SARS-CoV-2 Spike (kindly provided by Stefan Pöhlmann, DPZ, Göttingen, Germany) or with previously described pCG1-Spike encoding plasmids representing HCoV-NL63, -229E, -OC43, -HKU1.<sup>2</sup> For transfection, Fugene HD (Roche, Penzberg, Germany) was used in a Fugene to DNA ratio of 3:1. After 24 hours, the transfected VeroB4 cells were harvested and resuspended in DMEM/10% FCS to achieve a cell density of  $2.5 \times 10^5$  cells/ml. 50 µl of the cell suspension was applied to each incubation field of a multitest cover slide (Dunn Labortechnik, Asbach, Germany). The multitest cover slides were incubated for 6 hours before they were washed with PBS and fixed with ice-cold acetone/methanol (ratio 1:1) for 10 minutes. For the immunofluorescence test, the incubation fields were blocked by applying 5% non-fat dry milk in PBS/0.1% Tween for 30 minutes. Heat-inactivated patient sera (56°C, 30 minutes) were diluted in EUROIMMUN sample buffer (serial dilutions 1:10, 1:100, 1:1000, 1:10000) and 30 µl of the dilution was applied per incubation field. For IgM detection, IgG were depleted before applying sera to immunofluorescence tests. After 1 hour at room temperature, cover slides were washed 3 times for 5 minutes with PBS/0.1% Tween. Secondary detection was done using a 1:200 dilution of a goat-anti human IgG-Alexa488 (Dianova). After 30 minutes at room temperature, slides were washed 3 times for 5 minutes and rinsed with water. Slides were mounted using DAPI prolonged mounting medium (FisherScientific, Schwerte, Germany).

#### **c. Plaque reduction neutralization test (PRNT) for SARS-CoV 2**

Plaque reduction neutralization tests were done as described for MERS-CoV.<sup>3</sup> VeroE6 cells ( $4 \times 10^5$  cell/ml) were seeded in 24-well plates and incubated overnight. Prior to PRNT patient sera were heat-inactivated at 56°C for 30 minutes. For each dilution step (duplicate), patient sera were diluted in 200 µl OptiPro and mixed 1:1 with 200 µl virus solution containing 100 plaque forming units. The 400 µl

serum-virus solution was vortexed gently and incubated at 37°C for 1 hour. Each 24-well was incubated with 200 µl serum-virus solution. After 1 hour at 37°C the supernatants were discarded, the cells were washed once with PBS and supplemented with 1.2% Avicel solution in DMEM. After 3 days at 37°C, the supernatants were removed and the 24-well plates were fixed and inactivated using a 6% formaldehyde/PBS solution and stained with crystal violet as described <sup>4</sup>.

### 3. Supplementary table S1

**Table S1.** IgG immunofluorescence titers against endemic human CoVs

Patient ID	Day	OC43	NL63	HKU1	229E	Day	OC43	NL63	HKU1	229E
	p.o.	IgG	IgG	IgG	IgG	p.o.	IgG	IgG	IgG	IgG
#1	5	1000	1000	1000	100	15	1000	1000	1000	100
#2	4	1000	1000	100	100	13	10000	100	1000	10
#3	3	10000	100	1000	1000	16	10000	1000	10000	1000
#4	5	1000	100	100	100	17	10000	10	1000	100
#7	6	1000	100	1000	1000	13	10000	1000	10000	10000
#8	6	1000	100	1000	1000	10	10000	1000	10000	100
#10	6	1000	100	100	1000	11	10000	1000	100	1000
#14	na	na	na	na	na	5	100	100	100	100

#### 4. Supplementary Figures


**Figure S1**



**Figure S1. Sequence analysis of E gene sgRNA.**

The leader sequence (in purple), putative transcription regulatory sequences (TRS, in gray), and nucleotides coding for the 5'-proximal part of the E gene (yellow box) are shown. Oligonucleotide-binding sites used for amplification and RT-PCR detection are shown as green arrows, Taqman Probe as red arrow.

**Figure S2**



**Figure S2:**

Recombinant SARS-CoV-2 Spike-based immunofluorescence test shows seroconversion of patient #4. Representative outcome of a recombinant immunofluorescence test using serum dilutions 1:10, 1:100, 1:1000 and 1:10,000 of patient #4 at 5 and 17 days post onset of symptoms. Secondary detection was done by using a goat-anti human immunoglobulin labeled with Alexa488 (depicted in green).

## **5. Supplementary references**

1. Corman VM, Landt O, Kaiser M, et al. Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR. *Euro Surveill* 2020;25.
2. Corman VM, Muller MA, Costabel U, et al. Assays for laboratory confirmation of novel human coronavirus (hCoV-EMC) infections. *Euro Surveill* 2012;17.
3. Drosten C, Meyer B, Muller MA, et al. Transmission of MERS-coronavirus in household contacts. *N Engl J Med* 2014;371:828-35.
4. Herzog P, Drosten C, Muller MA. Plaque assay for human coronavirus NL63 using human colon carcinoma cells. *Virol J* 2008;5:138.